| scholarly article | Q13442814 |
| P50 | author | Tobias Maetzig | Q114410920 |
| Rainer Loew | Q114563947 | ||
| Axel Schambach | Q42229187 | ||
| Melanie Galla | Q42231242 | ||
| P2093 | author name string | Christopher Baum | |
| P2860 | cites work | Direct interaction of the U1 snRNP-A protein with the upstream efficiency element of the SV40 late polyadenylation signal | Q72718794 |
| Murine leukemia induced by retroviral gene marking | Q77975543 | ||
| Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells | Q81353679 | ||
| Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase | Q24535920 | ||
| LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 | ||
| Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration | Q28242708 | ||
| Mechanism and regulation of mRNA polyadenylation | Q29614774 | ||
| A third-generation lentivirus vector with a conditional packaging system | Q29616120 | ||
| Transcription start regions in the human genome are favored targets for MLV integration | Q29618456 | ||
| RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy | Q34342598 | ||
| Polyadenylation: a tail of two complexes. | Q35033251 | ||
| The upstream sequence element of the C2 complement poly(A) signal activates mRNA 3' end formation by two distinct mechanisms. | Q35207740 | ||
| Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells | Q35604467 | ||
| Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways | Q35642820 | ||
| Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity | Q35849232 | ||
| Retroviral insertional mutagenesis: past, present and future | Q36318150 | ||
| 3' end processing of the prothrombin mRNA in thrombophilia | Q36426645 | ||
| Definition of the upstream efficiency element of the simian virus 40 late polyadenylation signal by using in vitro analyses | Q36706227 | ||
| Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences | Q36761958 | ||
| The human immunodeficiency virus type 1 polyadenylylation signal: a 3' long terminal repeat element upstream of the AAUAAA necessary for efficient polyadenylylation | Q37426718 | ||
| The retroviruses human immunodeficiency virus type 1 and Moloney murine leukemia virus adopt radically different strategies to regulate promoter-proximal polyadenylation. | Q39605433 | ||
| Regulation of polyadenylation in hepatitis B viruses: stimulation by the upstream activating signal PS1 is orientation-dependent, distance-independent, and additive | Q40508994 | ||
| Sequences regulating temporal poly(A) site switching in the adenovirus major late transcription unit | Q40642300 | ||
| Upstream sequence elements enhance poly(A) site efficiency of the C2 complement gene and are phylogenetically conserved | Q40789024 | ||
| Distinct domains of AU-rich elements exert different functions in mRNA destabilization and stabilization by p38 mitogen-activated protein kinase or HuR. | Q40886532 | ||
| Sequence elements upstream of the 3' cleavage site confer substrate strength to the adenovirus L1 and L3 polyadenylation sites | Q41882662 | ||
| The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations | Q44826905 | ||
| A dissection of the cauliflower mosaic virus polyadenylation signal | Q45110213 | ||
| Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research | Q45857905 | ||
| Sequences 5' to the polyadenylation signal mediate differential poly(A) site use in hepatitis B viruses | Q46958551 | ||
| Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose | Q47334460 | ||
| Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. | Q54662841 | ||
| Context Dependence of Different Modules for Posttranscriptional Enhancement of Gene Expression from Retroviral Vectors | Q58195243 | ||
| Interaction between the U1 snRNP-A protein and the 160-kD subunit of cleavage-polyadenylation specificity factor increases polyadenylation efficiency in vitro | Q70988084 | ||
| CPSF recognition of an HIV-1 mRNA 3'-processing enhancer: multiple sequence contacts involved in poly(A) site definition | Q72427107 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1167-1173 | |
| P577 | publication date | 2007-04-03 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors | |
| P478 | volume | 15 |
| Q24648650 | 3' end mRNA processing: molecular mechanisms and implications for health and disease |
| Q39782235 | A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. |
| Q38317683 | A self-deletion lentiviral vector to reduce the risk of replication-competent virus formation |
| Q39856750 | Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. |
| Q35198350 | Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery |
| Q38073294 | Biosafety features of lentiviral vectors |
| Q58698412 | CRISPR/Cas9 Immunoengineering of Hoxb8-Immortalized Progenitor Cells for Revealing CCR7-Mediated Dendritic Cell Signaling and Migration Mechanisms |
| Q36102927 | Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells |
| Q45861548 | Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. |
| Q28066817 | Cross- and Co-Packaging of Retroviral RNAs and Their Consequences |
| Q39825383 | Cross-packaging of genetically distinct mouse and primate retroviral RNAs |
| Q27673743 | Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors |
| Q90440857 | Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders |
| Q37197942 | Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition |
| Q41948139 | Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy |
| Q40609634 | Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I. |
| Q37358032 | Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy |
| Q36644230 | Evading the immune response upon in vivo gene therapy with viral vectors. |
| Q35982211 | Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application |
| Q26859020 | Foamy virus vectors for HIV gene therapy |
| Q34223822 | Gammaretroviral vectors: biology, technology and application |
| Q39237421 | Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side |
| Q34556239 | Graded or threshold response of the tet-controlled gene expression: all depends on the concentration of the transactivator |
| Q21090483 | Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice |
| Q40208488 | Improved microRNA suppression by WPRE-linked tough decoy microRNA sponges. |
| Q34757266 | Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment |
| Q57174327 | In vivo imaging of the spatiotemporal activity of the eIF2 -ATF4 signaling pathway: Insights into stress and related disorders |
| Q37718180 | Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina |
| Q34668961 | Influence of untranslated regions on retroviral mRNA transfer and expression |
| Q64236162 | Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF |
| Q33713156 | Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors |
| Q37506025 | Integration-deficient lentiviral vectors: a slow coming of age. |
| Q33713951 | Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. |
| Q39689270 | Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector |
| Q34200828 | Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases |
| Q37684186 | Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons |
| Q33713427 | Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element |
| Q40003414 | Physiological promoters reduce the genotoxic risk of integrating gene vectors |
| Q26781432 | Progresses towards safe and efficient gene therapy vectors |
| Q37153580 | Recent advances in gene therapy for severe congenital immunodeficiency diseases |
| Q42692898 | Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors |
| Q34204409 | Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection |
| Q38879455 | Single-step cloning-screening method: a new tool for developing and studying high-titer viral vector producer cells. |
| Q42070127 | The U3 region of Moloney murine leukemia virus contains position-independent cis-acting sequences involved in the nuclear export of full-length viral transcripts |
| Q37143395 | The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy |
| Q37782290 | The use of cell-delivered gene therapy for the treatment of HIV/AIDS |
| Q37830029 | The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors |
| Q57493531 | Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout |
| Q34127579 | Translating Sleeping Beauty transposition into cellular therapies: victories and challenges |
| Q36341562 | Translation termination efficiency modulates ATF4 response by regulating ATF4 mRNA translation at 5' short ORFs |
| Q45863292 | Use of human MAR elements to improve retroviral vector production. |
| Q34082215 | Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors |
| Q39877036 | Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. |
| Q38800643 | Viral Vectors: The Road to Reducing Genotoxicity |
| Q38338190 | Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy |
| Q37262766 | Viral vectors: from virology to transgene expression |
Search more.